Is ALHC a Buy? What to Consider in 2026
Short answer
The bull case for Alignment Healthcare (ALHC) rests on Membership growth engine: ALHC has compounded health plan membership at roughly 30% per year since its 2021 IPO, reaching ~285,000 members in Q1 2026. Revenue (TTM) is ~$4.5B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. Whether ALHC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving roughly 285,000 members as of early 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings (generally in the 4 to 5 range) are central to the thesis because they drive bonus payments and help attract members. The investment picture is one of a growth company reaching an earnings inflection. Revenue grew about 33% year over year in Q1 2026 to ~$1.24 billion, and the company posted its first quarterly net income (~$11 million) after years of losses, while raising full-year guidance. The trade-off is valuation: with a trailing P/E in the hundreds, the stock discounts continued rapid membership growth and steady medical-cost discipline, leaving little room for execution stumbles or a cost-ratio reversal.
What's the case for buying ALHC?
1. Membership growth engine
ALHC has compounded health plan membership at roughly 30% per year since its 2021 IPO, reaching ~285,000 members in Q1 2026. Management guides year-end 2026 membership of 290,000 to 296,000, implying continued double-digit expansion. Sustained enrollment gains are the primary lever behind the revenue trajectory.
2. Margin and profitability inflection
Adjusted EBITDA rose about 88% year over year in Q1 2026 to ~$38 million, and the company reported its first quarterly net income. Adjusted medical benefit ratio improved to ~88.2% and adjusted SG&A leverage improved as revenue scaled. The story now hinges on proving these margins are durable, not one-quarter.
3. Star Ratings as a moat
Alignment has maintained high Star Ratings (roughly 4 to 5 stars) while some larger rivals saw ratings slip. Strong ratings unlock CMS bonus payments and make plans more attractive during annual enrollment, giving a smaller player a quality-based edge against national incumbents.
4. Technology-led cost control
The AVA platform and concierge care model are designed to manage chronic conditions and lower medical spend per member. If the technology continues to bend the medical cost curve as membership scales, operating leverage could widen; this is the core assumption embedded in the valuation.
What are the risks to ALHC?
Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, and risk coding directly affects revenue and bonus payments. The valuation is demanding, with a trailing P/E in the hundreds, so any growth deceleration or margin miss could drive a sharp de-rating. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits.
How is ALHC valued? (as of JULY 2026)
Snapshot for ALHC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$4.5B
- Q1 2026 revenue (YoY): ~$1.24B (+33%)
- 2026 revenue guidance: ~$5.14B to $5.19B
- Adjusted EBITDA (2026 guide): ~$133M to $163M
- Health plan members: ~285,000
- Market cap: ~$5B
ALHC recently crossed into profitability, posting ~$11 million of net income in Q1 2026 versus a prior-year loss, which leaves the trailing P/E extremely high (well over 100x) and makes the stock look expensive on current earnings. The bull case rests on forward growth and margin expansion rather than trailing profits. Shares traded around the low-to-mid $20s in mid-2026, near 52-week highs.
How do you decide if ALHC is a buy?
Rather than asking whether ALHC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALHC indirectly through an index or sector ETF before adding more.
For the full picture, see the ALHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALHC against your real portfolio and see your actual exposure before deciding.
The bottom line on ALHC
The bottom line: Alignment Healthcare's story right now is Membership growth engine, with revenue (ttm) at ~$4.5B. If you believe that narrative continues, the call is about sizing ALHC sensibly and checking overlap with what you own; if you doubt it (the risk: medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ALHC with Walnut
Use Alignment Healthcare as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ALHC a good stock to buy right now?
+
The case for Alignment Healthcare right now is Membership growth engine, with revenue (ttm) at ~$4.5B. If you believe that thesis holds, ALHC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Alignment Healthcare do?
+
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving roughly 285,000 members as of early 2026.
What are the main risks of ALHC?
+
Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, and risk coding directly affects revenue and bonus payments. The valuation is demanding, with a trailing P/E in the hundreds, so any growth deceleration or margin miss could drive a sharp de-rating. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits.
What does Alignment Healthcare do?
+
It runs Medicare Advantage health plans for seniors, combining a clinical care model, provider partnerships, and its AVA technology platform to try to deliver better outcomes at lower cost. Its members are concentrated in California and a few other states.
Is ALHC profitable?
+
It reached a profitability inflection in Q1 2026, reporting roughly $11 million of net income after years of losses, alongside positive and growing adjusted EBITDA. Whether that profitability is durable across a full year is the key open question.
How fast is ALHC growing?
+
Revenue grew about 33% year over year in Q1 2026, and membership has compounded near 30% annually since its 2021 IPO. Management guides 2026 revenue of roughly $5.14 to $5.19 billion.
Why is ALHC's P/E so high?
+
Because it only just turned profitable, trailing earnings are tiny relative to its ~$5 billion market cap, pushing the trailing P/E well over 100x. The valuation reflects expectations for future growth and margin expansion rather than current earnings.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ALHC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.